NRXP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 22:00):

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases...

Stats
Dagens volum	275 799
Gjennomsnittsvolum	214 215
Markedsverdi	37.13M
EPS	US089482100 ( 2024-03-28 )
Neste inntjeningsdato	( US089482100 ) 2024-05-14
Last Dividend	US089482100 ( N/A )
Next Dividend	US089482100 ( N/A )
P/E	-0.880
ATR14	US089482100.0280 (0.80%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-28	Rehnquist Janet	Buy	0
2023-09-13	Narido Richard Clavano	Buy	0
2023-08-30	Gorovitz Aaron	Buy	35 000	Common Stock, par value $0.001 per share
2023-08-30	Hurvitz Chaim	Buy	70 000	Common Stock, par value $0.001 per share
2023-08-23	Javitt Jonathan C	Buy	100 000	Common Stock

INSIDER POWER
2.82
Last 86 transactions
Buy: 35 919 718 \| Sell: 5 833 033

Volum Korrelasjon

Lang: 0.04 (neutral)

Kort: 0.47 (neutral)

Signal:(48.368) Neutral

NRx Pharmaceuticals, Inc. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

NRx Pharmaceuticals, Inc. Korrelasjon - Valuta/Råvare

0.15
( neutral )

0.20
( neutral )

0.00
( neutral )

0.03
( neutral )

0.00
( neutral )

0.53
( weak )

NRx Pharmaceuticals, Inc. Økonomi

Annual	2023
Omsetning:	US089482100
Bruttogevinst:	US08948210-5 000.00 (0.00 %)
EPS:	US08948210-3.98

FY	2023
Omsetning:	US089482100
Bruttogevinst:	US08948210-5 000.00 (0.00 %)
EPS:	US08948210-3.98

FY	2022
Omsetning:	US089482100
Bruttogevinst:	US08948210-4 000.00 (0.00 %)
EPS:	US08948210-0.540

FY	2021
Omsetning:	US089482100.00
Bruttogevinst:	US089482100.00 (0.00 %)
EPS:	US08948210-7.44

Financial Reports:

No articles found.

NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.